Sealantis develops surgical adhesive products based on its breakthrough
ALGA MIMETIC platform technology.
Sealantis translated the unique ability of algae to adhere to surfaces in wet
environment into a medical device to be used in a wide range of surgical
applications in the >$2.5B Biosurgicals market.
The company was founded at AMIT - Alfred Mann Institute at the Technion
by Prof. Havazelet Bianco-Peled, a renown biopolymer researcher.
Sealantis’ main product is a Gastro Intestinal (GI) Sealant. In millions of
surgical procedures on the gastro-intestinal (GI) system, surgical incisions
are made and then closed with sutures and \ or staples. While sutures and
staples are the standard of care for surgical wound closure, they are incapable
of water-tight sealing of wounds. Bowel content leakage from GI incisions is one
of the complications most dreaded by GI surgeons, due to its potential fatal implications.
In addition to the significant morbidity and mortality, GI anastomotic leaks
are associated with a 56% increase in the length of stay and with an additional
cost of $28,000 per patient on average.
Sealantis developed Seal-G, a Gastro-Intestinal (GI) bioresorbable sealant designed
to prevent leakage of bowel content from GI suture- or staple-lines thereby preventing
the morbidity and mortality associated with post-surgical leaks.